The US Food and Drug Administration (FDA) has cleared Novaliq’s Investigational New Drug (IND) application for NOV05, ...

From artificial intelligence and IOL innovation to biosimilars, geographic atrophy, and postoperative eye protection, Joshua ...

For optometrists, 2026 provides ample opportunity to continue the charge in advancements in dry eye, artificial intelligence ...

For patients for whom surgery is indicated but who are opposed to undergoing glaucoma surgery, he may suggest a different ...

FDA authorizes compassionate use of urcosimod for neuropathic corneal pain, a condition that causes severe pain and ...

Data estimates the prevalence of glaucoma currently is almost 50% higher than previously estimated and over 1.6 million ...

Prostaglandin analogues, such as latanoprost and bimatoprost, are the go-to therapies for glaucoma therapy. They continue to ...

The January 31, 2026, conference in Mainz, Germany, will focus on advances in optic neuropathy diagnosis, artificial ...

Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...

Nanoscope Therapeutics has received Pioneering Regenerative Medical Product (Sakigake) and Orphan Drug designations for ...

Digital Edition | Journals | Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the ...